RIPK1 and systemic inflammatory response syndrome: Together, these data suggest that RIPK1 and RIPK3 inhibitors might be effective in treating SIRS and related diseases by targeting not only necroptosis but also other pro-inflammatory conditions regulated by these kinases [106].